Benchmark initiated coverage on shares of Champions Oncology (NASDAQ:CSBR) in a research report released on Monday, Briefing.com Automated Import reports. The firm issued a buy rating and a $11.00 price objective on the biotechnology company’s stock.
A number of other analysts have also weighed in on the stock. Zacks Investment Research upgraded shares of Champions Oncology from a sell rating to a hold rating in a research note on Tuesday, September 24th. ValuEngine upgraded shares of Champions Oncology from a hold rating to a buy rating in a research note on Wednesday, October 2nd. Janney Montgomery Scott lowered shares of Champions Oncology from a buy rating to a neutral rating in a research note on Wednesday, July 24th. Finally, Roth Capital started coverage on shares of Champions Oncology in a research note on Friday, September 20th. They issued a buy rating and a $9.25 price target for the company. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Champions Oncology currently has an average rating of Buy and a consensus price target of $12.42.
NASDAQ:CSBR traded up $0.08 on Monday, reaching $5.20. 27,640 shares of the stock traded hands, compared to its average volume of 41,486. The company has a market capitalization of $62.63 million, a price-to-earnings ratio of 520.00 and a beta of 1.15. The company has a current ratio of 0.80, a quick ratio of 0.80 and a debt-to-equity ratio of 2.06. Champions Oncology has a 12 month low of $4.98 and a 12 month high of $13.24. The company’s fifty day simple moving average is $5.63 and its 200 day simple moving average is $7.00.
Several hedge funds have recently made changes to their positions in CSBR. Marshall Wace LLP purchased a new position in shares of Champions Oncology in the first quarter worth approximately $99,000. Susquehanna International Group LLP boosted its holdings in shares of Champions Oncology by 51.0% in the second quarter. Susquehanna International Group LLP now owns 24,510 shares of the biotechnology company’s stock worth $192,000 after buying an additional 8,279 shares during the last quarter. Wedge Capital Management L L P NC purchased a new position in shares of Champions Oncology in the second quarter worth approximately $277,000. Alambic Investment Management L.P. lifted its holdings in Champions Oncology by 27.0% during the second quarter. Alambic Investment Management L.P. now owns 68,681 shares of the biotechnology company’s stock valued at $538,000 after purchasing an additional 14,614 shares in the last quarter. Finally, Tocqueville Asset Management L.P. lifted its holdings in Champions Oncology by 69.1% during the third quarter. Tocqueville Asset Management L.P. now owns 134,568 shares of the biotechnology company’s stock valued at $760,000 after purchasing an additional 55,000 shares in the last quarter. Hedge funds and other institutional investors own 50.23% of the company’s stock.
About Champions Oncology
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
Recommended Story: What are the benefits of investing in REITs?
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.